687 related articles for article (PubMed ID: 18379296)
1. Update of prostate magnetic resonance imaging at 3 T.
Kim CK; Park BK
J Comput Assist Tomogr; 2008; 32(2):163-72. PubMed ID: 18379296
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer detection: comparison of T2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined.
Chen M; Dang HD; Wang JY; Zhou C; Li SY; Wang WC; Zhao WF; Yang ZH; Zhong CY; Li GZ
Acta Radiol; 2008 Jun; 49(5):602-10. PubMed ID: 18568549
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.
Yoshizako T; Wada A; Hayashi T; Uchida K; Sumura M; Uchida N; Kitagaki H; Igawa M
Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184
[TBL] [Abstract][Full Text] [Related]
4. Thirty-two-channel coil 3T magnetic resonance-guided biopsies of prostate tumor suspicious regions identified on multimodality 3T magnetic resonance imaging: technique and feasibility.
Hambrock T; Fütterer JJ; Huisman HJ; Hulsbergen-vandeKaa C; van Basten JP; van Oort I; Witjes JA; Barentsz JO
Invest Radiol; 2008 Oct; 43(10):686-94. PubMed ID: 18791410
[TBL] [Abstract][Full Text] [Related]
5. Comparison of phased-array 3.0-T and endorectal 1.5-T magnetic resonance imaging in the evaluation of local staging accuracy for prostate cancer.
Park BK; Kim B; Kim CK; Lee HM; Kwon GY
J Comput Assist Tomogr; 2007; 31(4):534-8. PubMed ID: 17882027
[TBL] [Abstract][Full Text] [Related]
6. Inter-reader agreement of multi-parametric MR imaging for the detection of prostate cancer: evaluation of a scoring system.
Quentin M; Arsov C; Röhlen S; Klasen J; Antoch G; Albers P; Blondin D
Rofo; 2012 Oct; 184(10):925-9. PubMed ID: 22744328
[TBL] [Abstract][Full Text] [Related]
7. [Multiparametric magnetic resonance imaging of the prostate - technique and clinical applications].
Franiel T
Rofo; 2011 Jul; 183(7):607-17. PubMed ID: 21487980
[TBL] [Abstract][Full Text] [Related]
8. MR imaging of the prostate at 3.0T with external phased array coil - preliminary results.
Morakkabati-Spitz N; Bastian PJ; Gieseke J; Träber F; Kuhl CK; Wattjes MP; Müller SC; Schild HH
Eur J Med Res; 2008 Jun; 13(6):287-91. PubMed ID: 18558555
[TBL] [Abstract][Full Text] [Related]
9. MR imaging and MR spectroscopy in prostate cancer management.
Katz S; Rosen M
Radiol Clin North Am; 2006 Sep; 44(5):723-34, viii. PubMed ID: 17030223
[TBL] [Abstract][Full Text] [Related]
10. Value of diffusion-weighted imaging for the prediction of prostate cancer location at 3T using a phased-array coil: preliminary results.
Kim CK; Park BK; Lee HM; Kwon GY
Invest Radiol; 2007 Dec; 42(12):842-7. PubMed ID: 18007156
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer detection with 3-T MRI: comparison of diffusion-weighted and T2-weighted imaging.
Miao H; Fukatsu H; Ishigaki T
Eur J Radiol; 2007 Feb; 61(2):297-302. PubMed ID: 17085002
[TBL] [Abstract][Full Text] [Related]
12. MR imaging of the prostate: 1.5T versus 3T.
Cornfeld DM; Weinreb JC
Magn Reson Imaging Clin N Am; 2007 Aug; 15(3):433-48, viii. PubMed ID: 17893061
[TBL] [Abstract][Full Text] [Related]
13. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy.
Haider MA; Chung P; Sweet J; Toi A; Jhaveri K; Ménard C; Warde P; Trachtenberg J; Lockwood G; Milosevic M
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):425-30. PubMed ID: 17881141
[TBL] [Abstract][Full Text] [Related]
14. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels.
Lawrentschuk N; Fleshner N
BJU Int; 2009 Mar; 103(6):730-3. PubMed ID: 19154475
[TBL] [Abstract][Full Text] [Related]
15. Functional magnetic resonance imaging in prostate cancer.
Seitz M; Shukla-Dave A; Bjartell A; Touijer K; Sciarra A; Bastian PJ; Stief C; Hricak H; Graser A
Eur Urol; 2009 Apr; 55(4):801-14. PubMed ID: 19185981
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the potential of diffusion-weighted imaging in prostate cancer detection.
Morgan VA; Kyriazi S; Ashley SE; DeSouza NM
Acta Radiol; 2007 Jul; 48(6):695-703. PubMed ID: 17611881
[TBL] [Abstract][Full Text] [Related]
17. Phased array magnetic resonance imaging for staging clinically localised prostrate cancer.
Borre M; Lundorf E; Marcussen N; Langkilde NC; Wolf H
Acta Oncol; 2005; 44(6):589-92. PubMed ID: 16294442
[TBL] [Abstract][Full Text] [Related]
18. MRI spectroscopy in screening of prostate cancer.
Goeb K; Engehausen DG; Krause FS; Hollenbach HP; Niedobitek G; Buettner M; Frangou P; Engelhard K
Anticancer Res; 2007; 27(1B):687-93. PubMed ID: 17348461
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging.
Tanimoto A; Nakashima J; Kohno H; Shinmoto H; Kuribayashi S
J Magn Reson Imaging; 2007 Jan; 25(1):146-52. PubMed ID: 17139633
[TBL] [Abstract][Full Text] [Related]
20. Analysis of prostate DCE-MRI: comparison of fast exchange limit and fast exchange regimen pharmacokinetic models in the discrimination of malignant from normal tissue.
Lowry M; Zelhof B; Liney GP; Gibbs P; Pickles MD; Turnbull LW
Invest Radiol; 2009 Sep; 44(9):577-84. PubMed ID: 19668002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
